New research indicates that tildrakizumab is increasingly prescribed to older patients suffering from plaque psoriasis with comorbid conditions. This recent study highlights its growing acceptance among dermatologists as a preferred treatment option due to its efficacy and safety profile. Plaque psoriasis is a chronic condition, and older patients often face additional health challenges that make treatment decisions more complex. Tildrakizumab, a monoclonal antibody targeting the IL-23p19 protein, has shown promising results in controlling psoriasis symptoms and improving patients’ quality of life. Doctors are opting for this biologic due to its lower risk of adverse effects compared to traditional therapies. The data reflects a trend towards more personalized treatment plans that address the unique needs of aging populations with chronic skin diseases. As awareness of its benefits spreads, tildrakizumab may become a mainstay in plaque psoriasis management.
Dermatology TimesNew data shows kindergarten readiness varies widely by income, cities step in to help
March 1, 2026
New data reveals a significant disparity in kindergarten readiness linked to income levels, highlighting an urgent need for educational intervention. Children from lower-income families often